

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS

Applicants respectfully request cancellation of claims 87 and 89-95 without prejudice to subsequent revival for prosecution in a continuation or divisional application.

Status of the claims

With entry of the instant amendment, claims 96-99 have been amended, new claims 104 and 105 have been added, and claims 89-95 have been cancelled. Claims 1-86 and 88 were previously cancelled. Therefore, claims 96-105 are currently pending.

New claim 104 recites a (monoclonal) antibody that is humanized. Support for the amendment can be found, *e.g.*, on page 32, lines 5-15.

The amendments to the claims add no new matter. Amended claim 96 and new claim 105 recite an antibody that achieves an effect of reducing tumor volume. Support for the term " tumor volume" can be found, *e.g.*, on page 119, lines 5-10. The additional amendments to claim 96 corrected typographical errors.

For convenience, the objections and rejections will be addressed in the order presented in the Office Action dated October 14, 2003.

Objection to claim 96

Claim 96 was objected to because of the typographical error in the term "proteinand". This error has been corrected in the amended claim.

Obviousness-type double patenting rejection

Claims 87, 89-93, and 94-103 were rejected for alleged obviousness-type double patenting over claims 1-3 of U.S. Patent No. 6,258,939 in view of Laus *et al.*

A terminal disclaimer and Certificate under 37 C.F.R. § 3.73(b) is submitted with this Amendment. The terminal disclaimer disclaims the terminal portion of the term of a patent granted on the instant application over U.S. Patent 6,258,939. U.S. Patent No. 6,258,939 and the subject application are commonly owned by the Regents of the University of California pursuant

to assignment of the rights of Urogenesys, now Agensys, in the application to the Regents of the University of California (a copy of the assignment recordation document is enclosed).

Applicants note that the filing of a terminal disclaimer to obviate a rejection based on non-statutory double patenting is not an admission of the propriety of the rejection. See, MPEP §804.02. Applicants therefore respectfully request withdrawal of the obviousness-type double patenting rejections.

Rejections under 35 U.S.C. § 102(e) and § 103

The rejection of claims 87, 90, and 92; and 87-95 under 35 U.S.C. § 102 and U.S.C. § 103, respectively, are moot in view of the cancellation of the claims.

Rejections under 35 U.S.C. § 112, first paragraph

Claim 95 has been cancelled, thereby obviating the rejection.

Claims 96 and 100-103 were rejected as allegedly failing to comply with the written description requirement. The Examiner alleges that the term "reduces tumor burden" is not supported in the specification. In order to expedite prosecution, claim 96 has been amended to recite "reduces tumor volume." Applicants believe that this amendment addresses the rejection and therefore respectfully request its withdrawal.

Rejections under 35 U.S.C. § 112, second paragraph

Claim 96 was rejected as allegedly indefinite in the recitation of the phrase "reduces tumor burden". As noted above, in order to expedite prosecution, the claim has been amended to recite "reduces tumor volume". This term refers to reduction of tumor mass, as taught in the specification, e.g., at pages 118-119. Applicants therefore respectfully request withdrawal of the rejection.

Appl. No. 09/855,632
Amdt. dated March 15, 2004
Amendment under 37 CFR 1.116 Expedited Procedure


PATENT

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Jean M. Lockyer', is written over the typed name and registration number.

Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:jml
60115165 v1

**SECRETARY OF STATE**

I, *BILL JONES*, Secretary of State of the State of California, hereby certify:

That the attached transcript of 3 page(s) has been compared with the record on file in this office, of which it purports to be a copy, and that it is full, true and correct.

IN WITNESS WHEREOF, I execute this certificate and affix the Great Seal of the State of California this day of

JUN 23 2001

A handwritten signature in cursive script that reads "Bill Jones".

Secretary of State

**CERTIFICATE OF AMENDMENT
OF
AMENDED AND RESTATED
ARTICLES OF INCORPORATION
OF
UROGENESYS, INC.**

ENDORSED - FILED
in the office of the Secretary of State
of the State of California

JUN 14 2001

BILL JONES, Secretary of State

The undersigned certify that:

1. They are the President and the Secretary, respectively, of UroGenesys, Inc., a California corporation.
2. Article One of the Amended and Restated Articles of Incorporation of this corporation is amended and restated in its entirety to read as follows:

"The name of the Corporation is Agensys, Inc. (the "Corporation")."
3. The Board of Directors has duly approved the foregoing amendment of Amended and Restated Articles of Incorporation.
4. The foregoing amendment of Amended and Restated Articles of Incorporation has been duly approved by the required vote of shareholders in accordance with Section 902 of the California Corporations Code. The total number of outstanding shares of the

corporation is 4,718,513 shares of Common Stock, 4,030,000 shares of Series A Preferred Stock and 4,520,000 shares of Series B Preferred Stock. The number of shares voting in favor of the amendment equaled or exceeded the vote required. The percentage vote required more than fifty percent (50%) of the outstanding shares of the Corporation.

We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Date: June 13th, 2001

Donald B. Rice, President

Alan C. Mendelson
Alan C. Mendelson, Secretary

corporation is 4,718,513 shares of Common Stock, 4,030,000 shares of Series A Preferred Stock and 4,520,000 shares of Series B Preferred Stock. The number of shares voting in favor of the amendment equaled or exceeded the vote required. The percentage vote required more than fifty percent (50%) of the outstanding shares of the Corporation.

We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Date: June 13th, 2001


Donald B. Rice, President

Alan C. Mendelson, Secretary



564,
09/329
- 14158045

OIPE JC102
MAR 18 2004
RECEIVED

FORM PTO-674
Expires 09/30/99
OMB 0651-0027

DEC 26 2001

01-16-2001

U.S. Department of Commerce
Patent and Trademark Office
PATENT



101583520

RECORDATION FORM COVER SHEET
PATENTS ONLY

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

- ☒ New
☐ Resubmission (Non-Recordation)
Document ID#
☐ Correction of PTO Error
Reel # Frame #
☐ Corrective Document
Reel # Frame #

Conveyance Type

- ☒ Assignment ☐ Security Agreement
☐ License ☐ Change of Name
☐ Merger ☐ Other
U.S. Government
(For Use ONLY by U.S. Government Agencies)
☐ Departmental File ☐ Secret File

Conveying Party(ies)

☒ Mark if additional names of conveying parties attached
Execution Date
Month Day Year
11122000

Name (line 1) Reiter, Robert E.

Name (line 2)

Second Party

Name (line 1) Witte, Owen N.

Execution Date
Month Day Year
11022000

Name (line 2)

Receiving Party

☒ Mark if additional names of receiving parties attached

Name (line 1) Regents of the University of California, The

Name (line 2)

Address (line 1) 1111 Franklin Street

Address (line 2) 12th Floor

Address (line 3) Oakland CA 94607-5200

☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment)

Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name

Address (line 1)

Address (line 2)

Address (line 3)

Address (line 4)

FOR OFFICE USE ONLY

01/12/2001 KTHAT1 00000300 09564329
01 FC:581 40.00 01

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

PATENT
REEL: 011417 FRAME: 0860

February 28, 2002

35 NORTH ARROYO PWY
SUITE 60
PASEDNA, CA 91103

This is to inform you that the document requested in your order dated 02-26-2002 is a true reproduction of the official office record copy of that document:

0114170860 CERTIFIED PATENT ASSIGNMENT-MAIL 1

Frames 0861 and 0862 missing

- ☒ The enclosed Patent Application as Filed is a reproduction of the application as originally filed and has been recorded using high quality scanning or microfilm equipment. Copies of page/papers that were not scannable have not been included, nor have pages/papers received after the original filing date. Copies of these pages/papers may be ordered separately.
- ☐ The enclosed document is a reproduction of the best available source of the official office record copy of that document.

If you have any questions or need additional information, please contact our Customer Service Department.

Mailing Address:

U.S. Patent and Trademark Office
Office of Public Records, Customer Service
Crystal Gateway 4, Suite 300
Washington DC 20231

Delivery Address:

U.S. Patent and Trademark Office
Office of Public Records, Customer Service
1213 Jefferson Davis Highway, Suite 300
Arlington VA 22202

For faster processing of new orders, please specify as appropriate:

Box 9 (Copy Sales) for Uncertified copies, or Box 10 for Certified copies of PTO Documents

Voice: (703) 308-9726 Fax: (703) 308-7048 E-Mail: PTCS@USPTO.GOV or Certdiv@USPTO.GOV

Ref:PS 530306

ASSIGNMENT

U.C. Case No. 97-575-9

For good and valuable consideration, the receipt of which is hereby acknowledge, ASSIGNOR (S),

1. Robert E. Reiter

2. Owen N. Witte

hereby sell, assign and transfer to ASSIGNEE, The Regents of the University of California, a California corporation, having its statewide administrative offices located at 1111 Franklin Street, 12th Fl., Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

and which is found in

- (a) _____ U.S. patent application executed _____, entitled as above and listing the above-named persons as inventors
- (b) X U.S. application serial no. 09/564,329, filed on May 3, 2000
- (c) _____ U.S. Patent No.: _____, issued _____

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension or substitute thereof, and any reissue, reexamination or extension of said Letters patent and all rights under all International Conventions for the Protection of Industrial Property:

ASSIGNOR (S) hereby covenants that no assignment, sale agreement or encumbrance has been or will be made or entered into which would conflict with his assignment;

Nov 9 2000 13:53 P. US

Fax: 626-395-0694

Patent & Trademark

REEL: 011417 FRAME: 086

ASSIGNOR (S) further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments, or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

And the ASSIGNOR (S) requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

executed this

12 day of November, 2000

____ day of _____, 200__

Signature of Inventor (s)

Robert E. Reiter
Robert E. Reiter

Owen N. Witte
Owen N. Witte

NOV 9 2000 13:53 P.04

Fax: 626-395-0694

Patent
Mandel & Horland

REEL: 011417 FRAME: 086

ASSIGNMENT

U.C. Case No. 97-575-9

For good and valuable consideration, the receipt of which is hereby acknowledge, ASSIGNOR (S),

1. Robert E. Reiter

2. Owen N. Witte

hereby sell, assign and transfer to ASSIGNEE, The Regents of the University of California, a California corporation, having its statewide administrative offices located at 1111 Franklin Street, 12th Fl., Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

and which is found in

- (a) _____ U.S. patent application executed _____, entitled as above and listing the above-named persons as inventors
- (b) X U.S. application serial no. 09/564,329, filed on May 3, 2000
- (c) _____ U.S. Patent No.: _____, issued _____

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension or substitute thereof, and any reissue, reexamination or extension of said Letters patent and all rights under all International Conventions for the Protection of Industrial Property:

ASSIGNOR (S) hereby covenants that no assignment, sale agreement or encumbrance has been or will be made or entered into which would conflict with his assignment;

PATENT
REEL: 011417 FRAME: 0865

ASSIGNOR (S) further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments, or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

And the ASSIGNOR (S) requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

executed this

Signature of Inventor (s)

_____ day of _____, 200_

2ND day of NOV, 2000

Robert E. Reiter

Owen N. Witte
Owen N. Witte

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR (S),

1. Douglas C. Saffran

2. Aya Jakobovits

hereby sell, assign and transfer to ASSIGNEE, UroGenesys, Incorporated, a California corporation, having its statewide administrative offices located at 1701 Colorado Avenue, Santa Monica, CA 90404, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

and which is found in

- (a) _____ U.S. patent application executed _____, entitled as above and listing the above-named persons as inventors
- (b) X U.S. application serial no. 09/564,329, filed on May 3, 2000
- (c) _____ U.S. Patent No.: _____, issued _____

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension or substitute thereof, and any reissue, reexamination or extension of said Letters patent and all rights under all International Conventions for the Protection of Industrial Property:

ASSIGNOR (S) hereby covenants that no assignment, sale agreement or encumbrance has been or will be made or entered into which would conflict with his assignment;

ASSIGNOR (S) further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments, or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

And the ASSIGNOR (S) requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, UroGenesys, Incorporated.

executed this

Signature of Inventor (s)

6th day of November, 2000

Douglas C. Saffran
Douglas C. Saffran

6 day of November, 2000

Aya Jakobovits
Aya Jakobovits

RECORDED: 12/26/2000

PATENT
REEL: 011417 FRAME: 0868